TIDMPRM

RNS Number : 6020P

Proteome Sciences PLC

01 September 2017

1 September 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Issue of Equity

Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") as payment for professional services.

Application has been made to the London Stock Exchange for the 533,333 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 7 September 2017.

After Admission, the total number of Ordinary Shares in issue will be 295,182,056 and the total number of voting rights will therefore be 295,182,056. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information:

 
 Proteome Sciences plc 
 Jeremy Haigh, Chief Executive                      Tel: +44 (0)20 7043 
  Officer                                            2116 
 Ian Pike, Chief Scientific 
  Officer 
 
 finnCap Limited (Nominated Adviser & Broker) 
 Geoff Nash/James Thompson                          Tel: +44 (0)20 7220 
  Tony Quirke (Broking)                              0500 
   IFC Advisory (Financial PR and IR) 
   Tim Metcalfe/Graham Herring/Miles              Tel: +44(0)2030538671 
    Nolan

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEOKDDKDBKDPCK

(END) Dow Jones Newswires

September 01, 2017 07:08 ET (11:08 GMT)

Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Proteome Sciences Charts.
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Proteome Sciences Charts.